Table 2.
Patient characteristics of the EGFR-TKIs group.
| Characteristics | Total, n (%) | TKI-BB, n (%) | TKI-RP, n (%) | p Value a |
|---|---|---|---|---|
| Age | 0.127 | |||
| ≧65 | 5 (25.0) | 1 (9.1) | 4 (44.4) | |
| <65 | 15 (75.0) | 10 (90.9) | 5 (55.6) | |
| Gender, n (%) | 0.028 | |||
| Male | 8 (40.0) | 7 (63.6) | 1 (11.1) | |
| Female | 12 (60.0) | 4 (36.4) | 8 (88.9) | |
| Smoking status, n (%) | 0.157 | |||
| Never smokers | 14 (70.0) | 6 (54.5) | 8 (88.9) | |
| Former or current smokers | 6 (30.0) | 5 (45.5) | 1 (11.1) | |
| ECOG PS, n (%) | 1.000 | |||
| 0–1 | 17 (85.0) | 9 (81.8) | 8 (88.9) | |
| 2–4 | 3 (15.0) | 2 (18.2) | 1 (11.1) | |
| Stage, n (%) | 0.189 | |||
| Stage 4A | 2 (10.0) | 0 (0.0) | 2 (22.2) | |
| Stage 4B | 18 (90.0) | 11 (100.0) | 7 (77.8) | |
| Baseline EGFR mutation status, n (%) | 0.525 | |||
| Exon 19 deletions | 7 (35.0) | 3 (27.3) | 4 (44.4) | |
| Exon 21 L858R | 12 (60.0) | 7 (63.6) | 5 (55.6) | |
| G719X + L861Q | 1 (5.0) | 1 (9.1) | 0 (0.0) | |
| Objective response rate | 80% | 71.4% | 0.659 | |
| Disease control rate | 90% | 100% | 0.497 |
a
By Fisher’s exact test.
BB, bevacizumab biosimilar; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; RP, reference product; TKI, tyrosine kinase inhibitor.